Clinical Trials on TCD in Belgium

Total 13 results

Universitaire Ziekenhuizen KU Leuven

Unknown

Long-term Follow-up in Patients With Deep Brain Stimulation (DBS) for Obsessive Compulsive Disorder (OCD).

Obsessive Compulsive Disorder (OCD)

Belgium
Groupe d'Etude Therapeutique des Affections Inflammatoires...
AbbVie; Gilead Sciences; Roche Pharma AG; Takeda; Celgene; Biogen

Active, not recruiting

Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD Patients in Clinical Remission at Baseline, Predictive of Sustained Clinical Remission Using a 2-year Follow up (CREDO2)

CD

Belgium, France
Groupe d'Etude Therapeutique des Affections Inflammatoires...
AbbVie; Gilead Sciences; Roche Pharma AG; Takeda; Celgene; Biogen

Completed

Crohn's Disease Endoscopic REmission Definition in an Objective Way (CREDO1)

CD

Belgium, France
Ziekenhuis Oost-Limburg

Active, not recruiting

Prevalence of NAFLD in T2DM Patients (PAD2ZOL)

Type 2 Diabetes | NAFLD | Fatty Liver, Nonalcoholic | T2D

Belgium
MicroPort CRM

Active, not recruiting

Observational Study on Inappropriate Therapies (OSIRIS)

Inappropriate Shocks From Implanted Defibrillator | ICD Replacement or Upgrade

Netherlands, United States, France, Spain, Belgium, Switzerland, Italy, United Kingdom, Germany, Austria, Portugal
Groupe d'Etude Therapeutique des Affections Inflammatoires...

Active, not recruiting

Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab (CURE)

CD

France, Belgium
Arcturus Therapeutics, Inc.

Recruiting

Study for Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810

OTC Deficiency | Ornithine Transcarbamylase Deficiency | OTCD

Spain, Belgium, United Kingdom, Sweden
AbbVie

Active, not recruiting

A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

Crohn's Disease (CD)

United States, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Romania, Slovakia, Spain, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients (STAND)

Sickle Cell Disease (SCD)

United States, United Kingdom, Germany, Spain, Greece, Italy, Brazil, Lebanon, Turkey, Belgium, France, Jordan, India, Finland, Canada, Colombia, Netherlands, Oman, South Africa, Panama, Ghana
Novartis Pharmaceuticals

Recruiting

Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

Sickle Cell Disease (SCD)

United States, Germany, Spain, Belgium, Italy, Lebanon, Brazil, Colombia, Oman, Switzerland, Turkey, United Kingdom, Canada, India, France
Takeda

Recruiting

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Crohn's Disease (CD)

United States, Australia, Israel, Belgium, Hungary, Canada, China, Croatia, Czechia, Greece, Italy, Japan, Korea, Republic of, Poland, United Kingdom, Lithuania, Slovakia, Spain
AbbVie

Active, not recruiting

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) (SEQUENCE)

Crohn's Disease (CD)

United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Slo... and more
Biogen

Completed

A Real-world Study of Imraldi® Use (PROPER)

Arthritis, Rheumatoid (RA) | Arthritis, Psoriatic (PsA) | Crohn's Disease (CD) | Colitis, Ulcerative (UC) | Axial Spondyloarthritis (axSpA)

Italy, United Kingdom, Germany, Belgium, Spain, Ireland

Clinical Trials on TCD in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations